MRTX-1719 is under clinical development by Mirati Therapeutics and currently in Phase II for Biliary Tumor. According to GlobalData, Phase II drugs for Biliary Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MRTX-1719 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRTX-1719 overview
MRTX-1719 is under development for the treatment of solid tumors including mesothelioma, pancreatic adenocarcinoma, non-small cell lung cancer, malignant peripheral nerve sheath tumor, bladder cancer, biliary tract tumors, melanoma and methylthioadenosine phosphoylase (MTAP)-deleted cancers. The drug candidate acts by targeting protein arginine methyltransferase 5 (PRMT5). It is administered through oral route.
Mirati Therapeutics overview
Mirati Therapeutics is a clinical-stage oncology company that carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 – pancreatic cancer and Sitravatinib – Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company has partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of MRTX-1719’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
